The Safety and Reliability of our Cold Plasma

Is our cold plasma safe?

 

Yes!

 

As you can see from the photo, our Adtec technician demonstrates touching the cold plasma jet.

 

An extensive list of practical tests and experiments were conducted during our first stage, pre clinical studies and ongoing post-market studies. This allowed us to carefully develop a cold plasma medical device that could bring all the antibacterial benefits but at the same time remain painless and contact-free so that it could be well tolerated in patient treatments. We were after all the first company worldwide to introduce cold plasma treatment on wounds demonstrated in our clinical trials.

 

As cold plasma can be generated through a variety of ways, they are also dependent on the plasma source design and surrounding environment. The components of plasma include reactive oxygen and nitrogen species and UV that need to be controlled to ensure they are within safe levels for medical use. Some plasma devices may also deliver fluctuating inconsistent cold plasma output as they are sensitive to changes in humidity and temperature in the treatment room. This may often result in undesirable side effects.

 

Because the Adtec SteriPlas is a low energy, microwave-powered, cold atmospheric argon plasma medical device this means its safety remains the main priority in line with delivering repeatable and successful results. It is also the reason why we are proud to state our medical device has NO side effects associated to it.


Our patented 6 electrode Cold Plasma Torch

The Adtec SteriPlas features a patented 6 electrode cold plasma torch. It’s proven efficacy for the destruction of all forms of bacteria including multi-resistant bugs makes it an alternative to antibiotic therapy for the treatment of wounds, surgical site infections and medical dermatology skin conditions. This is due to the unique physical mode of action delivered with our cold plasma as opposed to the chemical mode of action demonstrated with antibiotics. Broader studies have shown that antimicrobial resistance is unlikely to be generated with cold plasma treatment because of this.

 

A huge collection of our peer reviewed publications documents the clinical efficacy and safety of our medical device across a broad range of conditions including diabetic foot ulcers, left ventricular assist device (LVAD) infections, deep sternal wound infections, actinic keratoses and acne.

 

To learn more about our medical device or to obtain one in your clinic practice, please contact us at info@adtecplasma.com

 


Interested in becoming our medical distributor?

Our global presence is growing!

 

As cold plasma medicine continues to develop around the world, the Adtec SteriPlas has become widely adopted in more hospitals and clinics over the last 5 years.

 

If you are interested in becoming an exclusive medical distributor for our cold plasma medical devices, please contact us at info@adtecplasma.com where a member of our team will discuss how we can work together to achieve goals.

 


Adtec Healthcare's Conference and Exhibition attendance dates for 2022

As we look forward to a promising year ahead, please find the dates of our conference and exhibition participation for 2022:

Society for Cardiothoracic Surgery (SCTS) Annual Meeting – 8-10 May 2022

Malvern Diabetic Foot Conference – 11-13 May 2022

European Wound Management Association (EWMA) – 23-25 May 2022

Diabetic Foot Study Group (DFSG) – 16-18 September 2022

 

We hope to see you at either of these conferences and as always, we will have our flagship medical device, the Adtec SteriPlas, on demonstration ready for you to test and to see all the benefits linked to our cold plasma strengths for wounds, surgical site infections and medical dermatology.

 

 

 

 


Seasons Greetings from Adtec Healthcare

Seasons Greetings to everyone!

 

During this season, we take time to reflect upon the good things we have… like our partnership with you. We value each and every one of our customers, suppliers and partners and cannot express our gratitude enough for your ongoing support. We appreciate working with you and hope that the holidays and the coming year will bring you happiness and success.


Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications

 

We congratulate Dr Adam Bennett on his most recent publication, “Characterisation of a Cold Atmospheric Pressure Plasma Torch for Medical Applications: Demonstration of Device Safety”.

 

The safety and effectiveness of plasma devices are of crucial importance, especially for applications where the plasma is discharged near humans. This study presents the novel design and characterisation of a Cold Atmospheric Plasma torch (SteriPlas), which is used in medical applications. The study shows the characterisation methodology that must be undertaken to show that a plasma device is safe, especially when used in an application on human skin. The emission spectrum discharged from the plasma torch is shown. The UV emitted is measured and the effective irradiance is calculated. The effective irradiance enables the determination of the maximum UV exposure limits, which in this application are shown to be over two hours; however, in some applications may be only seconds. NOx and ozone emissions are also recorded. The NOx levels in this application are shown to be orders of magnitude lower than their safety limits and the ozone emissions are also shown to be safe; however, in some plasma technologies the NOx and ozone levels are orders of magnitude higher than the safe levels.

 

This paper concludes with a discussion of how safety limits vary in different regions around the world and proposes an international standard. It documents the safety of our medical device which further reiterates one of our main strengths where no side effects have been reported.

 

Access to the full paper can be found here: https://www.mdpi.com/2076-3417/11/24/11864


Successful meetings held at the Taiwan Society for Plastic Surgery

We are happy to report an eventful exhibition over the weekend at the Taiwan Society for Plastic Surgery led by our distributor in Taiwan. This is the first time the Adtec SteriPlas has set foot in Taiwan so naturally there was a lot of interest in our medical device. We look forward supporting our distributor for the exciting year ahead.

For more information about our medical device, contact us at info@adtecplasma.com


The first cold plasma medical device to treat Scleroderma

 

We congratulate Dr Stephanie Ardnt and Prof. Sigrid Karrer from the University Hospital Regensburg for their recent publication, “The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo”.

 

This publication features the use of our Adtec SteriPlas and shows strong efficacy for the treatment of Scleroderma, which up to now has not yet been evaluated by CAP. The extensive study documents significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. This study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.

 

https://doi.org/10.3390/biomedicines9111545


Deep Sternal Wound Infections (DWSI) and the Adtec SteriPlas

Unlike other cold plasma medical devices currently present on the market, the Adtec SteriPlas is not limited to the treatment of superficial wounds only.

 

For example, deep sternal wound infections (DSWIs) are a potentially devastating complication of median sternotomy performed in cardiac surgery. These large wound cavities are prone to infections and there is a concerningly high morbidity and mortality rate associated to these patients. The use of conventional therapies alone has shown to not always be successful and expensive muscle flap surgery is usually required.

 

The large 12cm2 treatment area of the Adtec SteriPlas covers a greater surface area of the wound compared to its competitors. This allows the benefit of a quick 2 minute treatment time for every 12cm2 covered. Because of its propulsion towards the treatment site, the cold plasma components work quickly to defeat bacteria and allow the management of the infection. The use of the Adtec SteriPlas has shown to accelerate healing rates and prevent the need for expensive surgery options that would otherwise have been needed.

 

It has been praised as a lifesaving medical device and is now widely used across multiple hospitals for the management of DWSIs.

 


Quick results achieved with the Adtec SteriPlas

How often do LVAD patients with infection need treatment with the Adtec SteriPlas?

 

We recommend a minimum treatment of twice per week. This applies to both outpatients in day clinics and inpatients who have been admitted into the wards.

 

The treatment time itself is as quick as 3 minutes. During these short minutes, the components of cold plasma quickly bombard the cellular structure of bacteria to create micropores which allows access to the microbial DNA for total destruction. This applies to all forms of bacteria regardless of their resistance profile or if they are protected within biofilm.

 

How quick have patients with LVAD infections healed?

 

Our clinical evidence has shown patients have healed in as quick of two weeks of treatment. These are patients who have failed previous therapeutic attempts with conventional treatment methods.